Science Fair Project Encyclopedia
Pentasa (TM) Mesalazine is one of the newer Aminosalicylates , a class of drug used as an anti-inflammatory.
Indication: treatment of mild to moderate ulcerative collitis and Crohn's disease (intestinal infammatory conditions)
Mesalazine is a bowel specific drug, that is metabolized in the gut and has its predominant actions there- thereby having fewer systemic side effects.
Mesalamine, also known as 5-aminosalicylic acid (5-ASA), is an anti-inflammatory drug used to treat inflammation of the rectum, mild to moderate ulcerative colitis and inflammation of the lower colon . Chemically, it is 5-amino-2-hydroxybenzoic acid. The empirical formula is C 7 H 7 NO 3 and its molecular weight is 153.14.
It is sold in the U.S. under the names:
- CANASA: Rectal suppository with 500 mfg of mesalamine in a base of Hard Fat NF.
- ROWASA: Rectal suppository & suspension enema .
- PENTASA: Suspension enema.
- ASACOL: Suspension enema & 400mg tablets
Known side effects
- Sudden severe stomach pain
- Bloody diarrhea
- Severe headache
- Hepatic impairment
- Agranulocytosis,Aplastic anaemia, Neutropenia, Thrombocytopenia- any sore throats, bruising or excesssive bleeding should be reported to the prescribing physician and a Full blood count (rbc and wbc) as well as liver function test be performed
Dosing depends on preparation- the UK guidelines from the British National Formulary are: Asacol: 400mg tablets- 6 tablets daily for an acute attack, tablets for prophylaxis. Not recommended for children
NB- preparations that lower stool pH (such as lactulose, a laxative) will affect the binding of Mesalazine in the bowel and will therfore reduce its efficacy.
Pentasa 4g daily for an acute attack, 1.5g daily for prohpylaxis
Sources for more information- British National Formulary, Davidsons Practice of Medicine, Oxford Textbook of Medicine, any other text book of medicine-
The contents of this article is licensed from www.wikipedia.org under the GNU Free Documentation License. Click here to see the transparent copy and copyright details